Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population

References

• Tang L, Gössl M, Ahmed A, et al. Contemporary reasons and clinical outcomes for patients with severe, symptomatic aortic stenosis not undergoing aortic valve replacement. Circ Cardiovasc Interv. 2018;11(12):e007220.
   PubMed Web of Science ®Google Scholar
• Sussell J, van Eijndhoven E, Schwartz TT, et al. Economic value of transcatheter valve replacement for inoperable aortic stenosis. Am J Manag Care. 2020;26(2):e50–6–e56.
   Web of Science ®Google Scholar
• Leon MB, Mack MJ, Hahn RT, PARTNER 3 Investigators, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77(9):1149–1161.
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Leon MB, Sheridan P, et al. Racial differences in the use of aortic valve replacement for treatment of symptomatic severe aortic valve stenosis in the transcatheter aortic valve replacement era. JAHA. 2020;9:e015879.
   Google Scholar
• Kang G, Kim JB. Expanding transcatheter aortic valve replacement into uncharted indications. Korean J Intern Med. 2018;33(3):474–482.
   PubMed Web of Science ®Google Scholar
• Charlson E, Legedza ATR, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. 2006;15(3):10.
   Web of Science ®Google Scholar
• Malaisrie SC, Tuday E, Lapin B, et al. Transcatheter aortic valve implantation decreases the rate of unoperated aortic stenosis. Eur J Cardio-Thorac Surg. 2011;40(1):43–48.
   PubMed Web of Science ®Google Scholar
• Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791.
   Google Scholar
• Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2021;77(4):450–500.
   PubMed Web of Science ®Google Scholar
• Mori M, Gupta A, Wang Y, et al. Trends in transcatheter and surgical aortic valve replacement among older adults in the United States. J Am Coll Cardiol. 2021;78(22):2161–2172.
   PubMed Web of Science ®Google Scholar
• Clark KA, Chouairi F, Kay B, et al. Trends in transcatheter and surgical aortic valve replacement in the United States, 2008–2018. Am Heart J. 2022;243:87–91.
   PubMed Web of Science ®Google Scholar
• Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76(21):2492–2516.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Magnuson EA, Lei Y, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2012;60(25):2683–2692.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Magnuson EA, Wang K, PARTNER Investigators, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (cohort B). Circulation. 2012;125(9):1102–1109.
   PubMed Web of Science ®Google Scholar
• Baron SJ, Wang K, House JA, On behalf of the PARTNER 2 Investigators, et al. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Results from the PARTNER 2 trial. Circulation. 2019;139(7):877–888.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–1607.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2012;60(6):548–558.
   PubMed Web of Science ®Google Scholar
• Baron SJ, Thourani VH, Kodali S, et al. Effect of SAPIEN-3 transcatheter valve implantation on health status in patients with severe aortic stenosis at intermediate surgical risk: results from the PARTNER S3i trial. JACC Cardiovasc Interv. 2018;11(12):1188–1198.
   PubMed Web of Science ®Google Scholar
• Baron SJ, Magnuson EA, Lu M, et al. Health status after transcatheter versus surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2019;74(23):2833–2842.
   PubMed Web of Science ®Google Scholar
• Herrmann HC, Thourani VH, Kodali SK, et al. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134(2):130–140.
   PubMed Web of Science ®Google Scholar
• Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2485–2491.
   PubMed Web of Science ®Google Scholar
• Baron SJ, Arnold SV, Wang K, PARTNER 2 Investigators, et al. Health status benefits of transcatheter vs surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk. JAMA Cardiol. 2017;2(8):837–845.
   PubMed Web of Science ®Google Scholar
• Heen AF, Lytvyn L, Shapiro M, et al. Patient values and preferences on valve replacement for aortic stenosis: a systematic review. Heart. 2021;107(16):1289–1295.
   PubMed Web of Science ®Google Scholar
• Coylewright M, Palmer R, O'Neill ES, et al. Patient‐defined goals for the treatment of severe aortic stenosis: a qualitative analysis. Health Expect. 2016;19(5):1036–1043.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Active ageing: a policy framework [Internet]. World Health Organization; 2002 [cited 2022 Jan 19]. Report No.: WHO/NMH/NPH/02.8. Available from: https://apps.who.int/iris/handle/10665/67215.
   Google Scholar
• Fries JF. The theory and practice of active aging. Curr Gerontol Geriatr Res. 2012;2012:420637.
   PubMedGoogle Scholar
• Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2017. Natl Vital Stat Rep. 2019;68(9):1–77.
   Google Scholar
• Gada H, Agarwal S, Marwick TH. Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: outcomes of a decision-analytic model. Ann Cardiothorac Surg. 2012;1(2):145–155.
   PubMedGoogle Scholar
• University of Michigan. Health and retirement study, consumption and activities mail survey public use dataset [Internet]; 2021 [cited 2021 Oct 1]. Available from: https://hrs.isr.umich.edu/about.
   Google Scholar
• Neumann PJ, Ganiats TG, Russell LB, et al., editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.
   Google Scholar
• Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and task force on practice guidelines. J Am Coll Cardiol. 2014;63(21):2304–2322.
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Foster J, Coylewright M, editors, et al. The medically managed patient with severe symptomatic aortic stenosis in the TAVR era: Patient characteristics, reasons for medical management, and quality of shared decision making at heart valve treatment centers. PLoS One. 2017;12(4):e0175926.
   PubMed Web of Science ®Google Scholar